, Tracking Stock Market Picks
Enter Symbol:
Gilead Sciences, Inc. (GILD) [hlAlert]

up 177.68 %

Gilead Sciences, Inc. (GILD) rated Overweight with price target $95 by Barclays

Posted on: Friday,  Feb 21, 2014  1:25 PM ET by Barclays

Barclays rated Overweight Gilead Sciences, Inc. (NASDAQ: GILD) on 02/21/2014. Previously Barclays rated Overweight Gilead Sciences, Inc. (NASDAQ: GILD) on 01/22/2013.,
when the stock price was $38.89. Since then, Gilead Sciences, Inc. has gained 177.68% as of 10/28/2015's recent price of $107.99.
If you would have followed the previous Barclays's recommendation on GILD, you would have gained 177.68% of your investment in 1009 days.

Gilead Sciences, Inc. (Gilead) is a biopharmaceutical company that discovers, develops, and commercializes therapeutics in areas of unmet medical need. The Company has United States and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Canada, France, Germany, Greece, Ireland, Italy, New Zealand, Portugal, Spain, Switzerland, Turkey, United Kingdom, and United States. Its commercial team promotes Truvada, Viread, Emtriva, Hepsera, AmBisome, Letairis, and Flolan through direct field contact with physicians, hospitals, clinics, and other healthcare providers. Gilead?s corporate partner, Astellas Pharma, Inc. (Astellas), promotes and sells AmBisome in the United States, Canada, Europe, Australia, and New Zealand. In May 2008, the Company acquired Navitas Assets, LLC?s. In April 2009, the Company announced the completion of its acquisition of CV Therapeutics, Inc.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
2/21/2014 1:25 PM Buy
83.10 95.00
as of 10/17/2014
1 Week down  -2.87 %
1 Month down  -2.97 %
3 Months up  18.43 %
1 YTD up  34.15 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/30/2013 1:25 PM Buy
72.64 74.00
7/26/2013 1:25 PM Buy
62.49 68.00
4/15/2013 2:25 PM Buy
51.24 65.00
1/22/2013 1:25 PM Buy
38.89 42.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy